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Abstract
Background: Acute malaria has been associated with a decreased antibody response to tetanus and diphtheria toxoids,
meningococcal, salmonella, and Hib vaccines. Interest in giving malaria drug therapy and prevention at the time of
childhood immunizations has increased greatly following recent trials of intermittent preventive therapy during infancy
(IPTi), stimulating this re-analysis of unpublished data. The effect of malaria chemoprophylaxis on vaccine response was
studied following administration of measles vaccines and diphtheria-tetanus-whole cell pertussis (DTP) vaccines.
Methods: In 1975, six villages divided into two groups of children ≤74 months of age from Burkina Faso, were assigned
to receive amodiaquine hydrochloride chemoprophylaxis (CH+) every two weeks for seven months or no
chemoprophylaxis (CH-). After five months, children in each group received either one dose of measles or two doses
of DTP vaccines.
Results: For recipients of the measles vaccine, the seroconversion rates in CH+ and CH- children, respectively, were
93% and 96% (P > 0.05). The seroresponse rates in CH+ and CH- children respectively, were 73% and 86% for diphtheria
(P > 0.05) and 77% and 91% for tetanus toxoid (P > 0.05). In a subset analysis, in which only children who strictly adhered
to chemoprophylaxis criteria were included, there were, likewise, no significant differences in seroconversion or
seroresponse for measles, diphtheria, or tetanus vaccines (P > 0.05). While analysis for pertussis showed a 43% (CH+)
and 67% (CH-) response (P < 0.05), analyses using logistic regression to control for sex, age, chemoprophylaxis, weight-
for-height Z-score, and pre-vaccination geometric mean titer (GMT), demonstrated that chemoprophylaxis was not
associated with a significantly different conversion rate following DTP and measles vaccines. Seven months of
chemoprophylaxis decreased significantly the malaria IFA and ELISA GMTs in the CH+ group.
Conclusion: Malaria chemoprophylaxis prior to vaccination in malaria endemic settings did not improve or impair
immunogenicity of DTP and measles vaccines. This is the first human study to look at the association between malaria
chemoprophylaxis and the serologic response to whole-cell pertussis vaccine.
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Background
Malaria accounts for an estimated 1 to 3 million deaths
each year, with the majority occurring in children under
five years of age in sub-Saharan Africa [1]. Vaccine-pre-
ventable diseases cause an estimated 1 to 2 million deaths
in African children [2]. The WHO's Expanded Program on
Immunization (EPI) is targeted at malarious areas,
emphasizing the need to understand the effect of malaria
and antimalaria drug use on vaccine immunogenicity and
efficacy. Accordingly, a study that began in 1975 has been
fully analysed following great increasing recent interest in
the important topic of malaria chemoprophylaxis and, in
particular, intermittent preventive (malaria) therapy of
infants (IPTi) [3-7].
Acute malaria has been associated with a decreased
response to tetanus toxoids, and meningococcal polysac-
charide, Hib conjugate, and whole cell vaccines for
typhoid fever [8-10]. Asymptomatic parasitaemia has
been associated with a decreased response to the newer
Malaria chemoprophylaxis and response to childhood vaccinations: flow chart of study design Figure 1
Malaria chemoprophylaxis and response to childhood vaccinations: flow chart of study design. Number of sub-
jects excluded from analysis due to moving, death or lack of available sera: 1. 4 (37 excluded due to detectable pre-vaccination 
measles antibody titers) 2. 163 3. 177 4. 162 5. 70 6. 66 7. 36 8. 31 (68 excluded due to detectable pre-vaccination measles 
antibody titers, 18 excluded due to receipt of some prophylaxis)Malaria Journal 2005, 4:53 http://www.malariajournal.com/content/4/1/53
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acellular pertussis and meningococcal vaccines, suggest-
ing a benefit from malaria prophylaxis prior to vaccina-
tion [11-13]. Other studies have shown that
asymptomatic parasitaemia or anti-malarial drug admin-
istration does not inhibit vaccine response to various live,
attenuated, whole-cell killed, and toxoid vaccines [4,5,14-
20]. No human studies have looked at the association
between parasitaemia and the serologic response to
whole-cell pertussis vaccine, a product still used in many
vaccination programmes, particularly in developing coun-
tries. Antimalarials may also depress vaccine response as
illustrated by the immunodepressive effect of 4-amino-
quinolones[13,21-24].
The study aimed to determine the effect of malaria chem-
oprophylaxis on vaccine seroconversion or seroresponse
to live, attenuated measles vaccine, diphtheria and tetanus
toxoids and whole-cell pertussis (DTP) vaccines.
Methods
Study area and population
The study was conducted from May through December in
1975 in six villages; all were located in the Guinean
savanna and were hyper- and holo-endemic for malaria,
depending on transmission season [25]. Before the study
began (February-March, during the low transmission sea-
son), a 52% Plasmodium falciparum parasitaemia preva-
lence was found in 150 children (25 per site) <6 years of
age, with no major differences between the sites; during
this pre-study investigation, antibodies to P. falciparum
were detected by indirect haemagglutination (IHA) in 100
percent of children tested from five of the six villages (25
children per village). Burkinabe clinicians in the nearest
dispensaries and hospitals stated that the study area was
endemic for measles (cases and deaths occurred during
the study), diphtheria, tetanus, and pertussis, but the inci-
dence was unknown; routine data had not been collected
from the study villages because the EPI had not yet begun
[26]. Hence, previous vaccination of children was
extremely unlikely and was confirmed by interrogation of
individual families. There was no malaria prophylaxis;
treatment for fevers and other illness was obtained from
traditional healers and in dispensaries within five km of
the villages. P. falciparum resistance to 4-aminoquinolo-
nes was unknown in the area. Exclusion criteria for partic-
ipation in the study included acute or chronic severe
illness and the presence of detectable pre-vaccination
measles antibodies. Children were weighed with a cali-
brated hanging scale. The length of very young children
was measured with them lying down on a calibrated
board and, for older children, standing, according to
Centers for Disease Control and Prevention (CDC) nutri-
tion programme guidelines.
Study design
Children, aged 4 to 74 months (N = 996) living in the 6
malarious villages were assigned to 2 groups of 3 villages
each, depending on whether they lived in villages east or
west of Bobo-Dioulasso. One group received amodi-
aquine prophylaxis, CH+ [N = 488], and the other
received no prophylaxis, CH- [N = 508]. Virtually all chil-
dren within the same village received either measles [N =
482], or DTP vaccine [N = 514] (Figure 1). The study vil-
lages had differing populations of target-aged children.
Hence, village and subject separation into measles versus
DTP groups was based on the estimated number of chil-
dren needed for each vaccine, and was dependent on the
initial calculation of sample size (see Statistical Analysis).
There was no blinding of study participants or researchers.
The populations were of a related Mandinke ethnic group
(Bobo in the eastern and Senufo in the western villages)
and the communities had similar Anopheles gambiae ecol-
ogy. Villages were chosen, based on the level of endemic-
ity of malaria, the immunologic naivete of those receiving
immunizations, and their proximity to one another; vil-
lages were spaced far enough apart so that families in CH-
villages did not know that children in CH+ villages were
receiving chemoprophylaxis, yet were close enough
(within 75 km of Bob-Dioulasso) for travel convenience
and management by the research team.
Chemoprophylaxis
CH+ children received a single prophylactic dose of amo-
diaquine hydrochloride suspension or tablets every 2
weeks for 7 months beginning in May and June, the start
of the transmission season; those <12 months of age
received 100 mg, those 12 to 47 months received 200 mg,
and those 48 to 73 months old received 300 mg. Both
amodiaquine and chloroquine are 4-aminoquinolines.
Amodiaquine is the prodrug for the active ingredient
desethylamodiaquine (DAQ). DAQ has a terminal half
life of one to three weeks and is schizonticidal in very low
concentrations [27,28]. While amodiaquine lost favour
because of its association with agranulocytosis, the drug is
now being re-evaluated. Because amodiaquine has not
been used for over 2 decades, it has somewhat greater effi-
cacy than chloroquine for P. falciparum resistant to chlo-
roquine [29,30].
Seroconversion rates were measured in all CH+ and CH-
children for whom paired sera were available. In addition,
a CH+ group having strict compliance to drug ingestion
was analyzed to examine more carefully the effect of
malaria or drug use on serconversion and seroresponse.
For this study, criteria for strict compliance included:
receipt of ≥75% of the doses, no two consecutive doses
missing, no doses missed in the month prior to vaccina-
tion(s), and no doses missed between the second vaccina-Malaria Journal 2005, 4:53 http://www.malariajournal.com/content/4/1/53
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tion and the last blood draw. At study completion, during
the beginning of the low transmission season, families of
children in the CH+ group were given a short-term supply
of amodiaquine prophylaxis and instructions for home
treatment in case of a rebound malaria attack. Follow-up
visits occurred every one to two months in all villages for
six months after the study.
Vaccination
All children were vaccinated with either measles vaccine
or the first dose of DTP at month 5 (October or Novem-
ber, peak malaria transmission) and the second DTP dose
one month later. Two doses of DTP were given during the
study (rather than the standard initial series of three
doses) to increase the likelihood that any effect from che-
moprophylaxis would be discerned; a third dose was
given at the end of the study but bloods were not drawn
after this third vaccination. Vaccinations and amodi-
aquine were administered on the same day. The manufac-
turer and source of the licensed vaccines used were the
Dow, Lirugen (Schwarz strain) measles vaccine, Lot No.
185806 AA and Merrill-National DTP, adsorbed, USP,
vaccine, filling number 1036 DM, bulk Lot No. 1832.
Measles and DTP vaccines were injected intramuscularly
(0.5 ml) via a hydraulic (pressurized), injection device,
the Ped-O-Jet® injector. Following study completion, all
children in participating villages received the vaccine that
they did not receive during the study. Prior to use, the
measles and DTP vaccines were tested for potency and met
standard requirements.
Vaccine serology
Venous blood samples were kept refrigerated and within
1 to 3 days serum was separated and kept at -20°C prior
to shipment to the CDC, Atlanta, Georgia, USA, in dry ice.
Serologic testing for the measles vaccine was performed in
1977 at the then Virology Division, Bureau of Laborato-
ries, CDC. Antibody response to the DTP vaccine was per-
formed in 1977 at the then Division of Bacterial Products,
Bureau of Biologics, Food and Drug Administration, in
Bethesda, MD.
Measles antibody was assessed by haemagglutination
inhibition [31-33]. Seroconversion was defined by a rise
in titer to ≥1:20 from an initial titer of <1:10 (the lowest
detectable titer). Diphtheria and tetanus antibody titers
were measured by passive microhemagglutination, using
tanned sheep red blood cells [34,35]. Individuals showing
a >4-fold rise in antibodies to uncoated sheep red blood
cells were not included in the analysis. Pertussis titers were
measured by microagglutination using killed cells of Bor-
detella pertussis strains 134 and 165 [36]. The titer is the
log2 of the reciprocal of the highest final serum dilution
resulting in detectable agglutination. When sufficient
serum was available, the lowest final serum dilution
tested was 1:8; by convention, samples negative at a 1:8
dilution were assigned the titer log2 = 2. If the serum sam-
ple volume was low, higher initial dilutions were used.
When such sera were negative at the lowest dilution
tested, the titer was reported as <lowest dilution tested.
Because the actual end-point was not known, titers for
these sera were not included in the calculation of geomet-
ric mean titer (GMT) or geometric mean fold rise in titer
(GMR). For some individuals, it was possible to verify a
≥4-fold rise even if the actual endpoint was not known for
both sera. A ≥4-fold rise for DTP antigens was considered
positive. For DTP, in cases where the titer decreased from
pre- to post-vaccination, a ∆GMT = 0 was used in the cal-
culation of GMR.
Malaria serology
P. falciparum IgG antibodies were measured by the
Immunofluorescence Assay (IFA) [37] and by the
Enzyme-Linked Immunosorbent Assay (ELISA) [38] fol-
lowing collection of blood 7 months after the children
were CH+ or CH- status.
Table 1: Characteristics of children qualifying for analyses at vaccination by vaccine type, gender, age and nutrition (measured by the 
Weight-for-Height Z-score at vaccination) for the prophylaxis (CH+) and no prophylaxis (CH-) groups.
Prophylaxis (CH+) No Prophylaxis (CH-)
Vacci ne Type Trait # % or Mean (SD*) # % or Mean (SD*) P-value
Measles Sex % male 177 53 274 54 0.82
Age in months 178 33.7 (15.2) 274 33.7 (18.1) 0.97
Wt-for-Ht Z-score 162 -0.65 (0.92) 247 -0.54 (1.01) 0.28
DTP Sex % male 310 48 204 53 0.04
Age in months 309 32.3 (14.9) 204 32 (17.7) 0.29
Wt-for-Ht Z-score 210 -0.88 (0.98) 37 -0.78 (0.84) 0.29
* SD Standard DeviationMalaria Journal 2005, 4:53 http://www.malariajournal.com/content/4/1/53
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Statistical Analysis
Sample size was determined initially by a method com-
paring two proportions. For measles, 215 subjects were
required for each group in order to have 90% assurance of
significant results to detect this 10% difference in
response rates. Similarly, for DTP vaccines, assuming 70%
seroconversion for the test group and 60% for the control
group, 387 subjects were needed for each group. SAS soft-
ware, version 9.00 (SAS Institute, USA), was used. Weight-
for-height Z-score was calculated using an anthro-system
(version 1.02, WHO-CDC, Switzerland).
The primary outcome was rate of seroconversion or
seroresponse in CH+ and CH- individuals. As secondary
outcomes, geometric mean titers (GMT) and mean fold
rise in titer (GMR) were measured for measles, DTP, and
malaria antibodies for CH+ and CH- individuals for the
strict compliance group.
Study population characteristics at vaccination were com-
pared for the CH+ and CH- children using the Chi-
squared test and Student's pooled t-test. The Chi-squared
test was used for comparison of seroconversion to measles
vaccine and seroresponse to DTP vaccinations; the Stu-
dent's pooled t-test was used for pre- and post-vaccination
GMT and GMR. A univariate logistic analysis was per-
formed to assess effects of sex, age (> or < 24 months),
prophylaxis, weight-for-height Z-score (> or < median Z-
score), and pre-vaccination GMT (> or < median GMT) on
seroconversion or seroresponse. Multivariate logistic
regression was performed on those factors found to be
independently associated with seroresponse. Analyses for
seroconversion, GMTs, GMRs, and logistic regression were
adjusted for village effect.
Consent
The study protocol was approved by the Burkina Faso
(Upper Volta) Ministry of Health and the Institutional
Review Board at the CDC. Verbal permission for the study
was obtained from the village chiefs, their "council of
elders," and each participating family, as was the custom
for working in Burkinabe villages.
Results
The groups were similar at baseline with regard to age, sex,
and nutritional status, except for a slight excess of males
in the CH- group for DTP (Table 1). Twenty percent of the
children were <12 months of age (N = 202). Figure 1
shows the distribution flow of children receiving or not
receiving chemoprophylaxis by vaccine type. Although
the vaccine was administered as combined DTP, the
number of children with serological data that were evalu-
ated differed for the three DTP assays as defined above.
The final number of children analysed reflects the availa-
bility of paired sera, or loss due to moves or death (Figure
1). When comparing the compliant CH+ children to the
non-compliant CH+ children, there were no significant
differences in sex, age, or weight-for-height Z-score for
those children receiving measles vaccine (P = 0.33, 0.56,
0.52 respectively) or in sex for children receiving DTP (P
= 0.22). For the DTP group, age and weight-for-height Z-
score was significantly less in the noncompliant CH+
group (P < 0.01, P = 0.02, respectively).
Table 2 shows that seroconversion rates to measles vac-
cine and seroresponse to diphtheria and tetanus vaccines
were not significantly different in the CH+ and CH-
groups, both when all children were included and when
non-compliant CH+ children were excluded from the
Table 2: Seroconversion to measles, diphtheria, tetanus, and pertussis vaccinations in the prophylaxis (CH+) and no prophylaxis (CH-) 
groups
Vaccine Proportion With Seroconversion or Serore-
sponse (%)†
P-value 
(Adjusted For Village)
Relative Risk (95% CI)
CH+ CH-
Measles 127/137(93)* 180/187 (96) 0.16* 0.96 (0.91–1.02)*
109/116 (94) 0.36 0.98 (0.92–1.03)
Diphtheria 108/147(73)* 116/135 (86) 0.26* 0.86 (0.76–0.96)*‡
38/ 46 (83) 0.59 0.96 (0.83–1.12)
Tetanus 104/134(77)* 126/138 (91) 0.08* 0.85 (0.77–0.94)*‡
41/43 (95) 0.39 1.04 (0.96–1.14)
Pertussis 63/148(43) * 113/168 (67) <0.01* 0.63 (0.51–0.78)*
17/44 (39) <0.01 0.57 (0.39–0.85)
* top rows include all CH+ children (bottom rows include only those CH+ children who met criteria for strict compliance)
† seroconversion is any increase in titer from a negative baseline for measles; seroresponse is a four-fold or greater rise in titer for diphtheria, 
tetanus, and pertussis
‡ the discordance between the P-value and confidence interval arises because the latter was calculated from a separate analysis which did not adjust 
for the random effect of villageMalaria Journal 2005, 4:53 http://www.malariajournal.com/content/4/1/53
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analysis (P > 0.05). When all children were included in
this analysis, there was a lower rate of seroconversion to
diphtheria and tetanus in the CH+ group, but this differ-
ence was not statistically significant. Percent seroresponse
to pertussis was greater in the CH- group (P < 0.01). In this
cluster analysis, there was adjustment for the random
effect of village. When the analysis was done without
adjusting for the random effect of village, there was a sig-
nificantly greater rate of seroconversion to diphtheria and
tetanus in the CH- group. When non-compliant children
were excluded, the difference was no longer significant for
diphtheria and tetanus. Percent seroresponse to pertussis
remained greater in the CH- group (P < 0.01).
For measles, pre-vaccination measles titers for all children
were <1:10 (lowest detectable titer) (Figure 2); GMR was
not significantly different in the CH+ vs. CH- group (P =
0.44). For all three antigens GMR was higher in the CH-
group, but this difference was statistically significant only
for pertussis (P < 0.01).
Multivariate logistic regression analysis indicated that for
tetanus, a lower pre-vaccination GMT was positively asso-
ciated with seroresponse (P = 0.02); for pertussis, a lower
pre-vaccination GMT (P < 0.01) and younger age (P =
0.04) were positively associated with seroresponse. There
was no significant difference in pre-vaccination pertussis
titres between the CH+ and CH- group (P 0.22) when
looking at all children regardless of compliance; however,
when excluding non-compliant children, pre-vaccination
pertussis titres were higher in CH+ children (P <0.01).
While pre-vaccination pertussis titres were higher in com-
pliant CH+ children (log2 of GMT = 6.19, N = 37) com-
pared to non-compliant CH+ children (log2 of GMT =
5.80, N = 84), this difference was not significantly differ-
ent (P = 0.80). Chemoprophylaxis was not associated
with seroresponse for any of the vaccines. Thus, especially
for pertussis, the lower vaccine response rate observed in
the CH+ group appears to be due, in part, to the greater
proportion of subjects with high pre-immunization titers.
Malaria antibody titers were significantly lower in the
CH+ group compared to the CH- group following seven
months of prophylaxis. GMTs for children receiving mea-
sles vaccine were: CH+, 196 (N = 128) vs. CH-, 1089 (N =
219) (P < 0.01) using IFA and CH+, 285 (N = 60) vs CH-
, 1990 (N = 64) using ELISA (P < 0.01) and for children
receiving DTP vaccine: CH+, 109 (N = 132) vs CH-, 178
(N = 178) (P < 0.01) using IFA and CH+, 86 (N = 63) vs
CH-,153 (N = 30) (P = 0.01) using ELISA. Only 13 percent
of all CH+ children with detectable malaria titers prior to
chemoprophylaxis had undetectable titers post-chemo-
prophylaxis (N = 159). This indicates that chemoprophy-
laxis given to young children for five to seven months after
previous exposure to malaria was not adequate to elimi-
nate malaria antibodies.
No adverse events were recorded after chemoprophylaxis,
blood sample collection, or vaccination other than a few
children with 1–3 mm nodules on their arms after receiv-
ing the vaccine by injector and one child who developed
a cellulitis where the venopuncture occurred: this child
recovered with systemic antibiotic treatment.
Discussion
Proposed mechanisms for malaria-associated immunode-
pression include impaired macrophage function [39-41],
altered cytokine production [39,42], a depletion of T or B
cells [43], impaired dendritic cells[42,44,45], elevated
nitric oxide production [46] and elevated prostaglandin E
during febrile malaria[47]. Clinical evidence includes an
association of malaria with increased susceptibility to bac-
terial infections [48], reactivation of viral infections
[49,50], a low prevalence of autoimmune disease in
endemic areas[51,52], and reports of decreased responses
to vaccinations.
In contrast to asymptomatic parasitaemia, acute malaria
impairs vaccine response[8-10,12,17,18,20]. In vitro chal-
lenge studies in individuals with acute malaria have dem-
onstrated a depression in the cellular immune response
involving alterations in lymphoproliferation and cytokine
responses [42,53,54]. The pyrogenic cytokine TNF-alpha
Pre and post-vaccination Geometric Mean Titers (GMTs)  and Geometric Mean Fold Rise (GMR) for prophylaxis (CH+)  and no prophylaxis (CH-) groups Figure 2
Pre and post-vaccination Geometric Mean Titers 
(GMTs) and Geometric Mean Fold Rise (GMR) for 
prophylaxis (CH+) and no prophylaxis (CH-) groups. 
P values listed correspond to the difference in GMR between 
the two groups. GMTs expressed as log2. Children included 
in the CH+ group met criteria for compliance for chemo-
prophylaxis. (A) Measles vaccine: GMR for CH+ and CH- 
groups does not differ significantly. (B) Diphtheria vaccine: 
GMR for CH+ and CH- groups does not differ significantly. 
(C) Tetanus vaccine: GMR for CH+ and CH- groups does 
not differ significantly. (D) Pertussis vaccine: GMR is signifi-
cantly > for CH- group.Malaria Journal 2005, 4:53 http://www.malariajournal.com/content/4/1/53
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is elevated in febrile malaria and may depress humoral
immunity by impairing antigen handling by dendritic
cells. T-cell levels, CD4 cells in particular, are depressed
[55]. IL-1, in addition to TNF-alpha, is elevated in acute
illnesses [56,57]. Both promote increased T-cell adhesion
to endothelium, which may lead to T-cell margination
and sequestration and, thus, a decrease of functional T-
cells [55]. CD4 cells secrete cytokines that activate CD8
cells, B-cells and macrophages. In acute malaria, a depres-
sion of CD4 cells leads to depressed cellular and humoral
immunity, impairing vaccine response.
The absence of association between malaria chemoproph-
ylaxis and vaccine response in this study is consistent with
findings from other chemoprophylaxis studies in malari-
ous areas involving children with asymptomatic parasi-
taemia [4,5,14,16-18,58]. No prior studies have
published data on the association between chemoproph-
ylaxis and pertussis (killed, whole-cell) vaccine response
in humans.
The agglutination test remains the test of choice for
whole-cell pertussis vaccines. Although the antigen-spe-
cific ELISA tests can amplify the information provided by
the agglutination test, the agglutination test is the only
one that has been shown clinically to correlate with vac-
cine efficacy of whole-cell pertussis vaccines and has been
used in relatively recent trials [59,60]. Although ELISA or
cell-culture based methods are more widely used today
than the passive haemagglutination method for tetanus
and diphtheria antitoxins, passive haemagglutination
remains acceptable for evaluations of immunized popula-
tions [61]. Had they been available, the newer serological
tests for measles, including neutralization testing, would
have provided greater insight regarding clinical protection
from disease.
Results of this study indicated that for the pertussis com-
ponent, children <24 months of age had a better serore-
sponse. Vaccinating children <24 months of age will more
effectively target the population in greatest need. Pertussis
is most serious for very young infants and because compli-
cations leading to hospitalization, pneumonias, and
death occur most often in those <24 months of age, the
recommended age for initiation of pertussis immuniza-
tion is generally two to three months.
Three doses of DTP vaccine comprise the usual primary
series;thus, it would have been useful to assess serocon-
version after a third DTP dose in addition to the response
following the second dose. Technical and logistical con-
siderations precluded this; additionally, there was con-
cern regarding the possibility of decreased compliance
with a longer study, as well as the potential to minimize
any differences in the effect of chemoprophylaxis on sero-
conversion.
Malaria serologies demonstrated a significant difference
in GMTs between the two treatment groups at the time of
vaccination, adding some assurance that chemoprophy-
laxis decreased asymptomatic parasitaemia. Despite
assumed effective chemoprophylaxis for five to seven
months, virtually all compliant children had malaria anti-
bodies; this probably reflected a durable antibody
response to infections acquired before the study began.
While not the primary study objective, fever prevalence
data and blood smear records would have provided valu-
able insight on malaria prevention in the chemoprophy-
laxis group. Given efforts to administer intermittent
preventive therapy of infants (IPTi) in conjunction with
the vaccines included in the EPI, additional prospective
studies are needed to establish more firmly the effect of
antimalarials on response to childhood vaccinations [6].
Conclusion
Malaria chemoprophylaxis does not appear to enhance
nor impair the antibody response to DTP and measles vac-
cines. There have been several changes over the 30 years
since the study completion, including development of fal-
ciparum malaria resistance to 4-aminoquinolones
throughout Africa, and establishment of the EPI (1977)
and the Roll Back Malaria Partnership (1998). The contin-
uing development and deployment of new antimalarial
drugs and childhood vaccines mandates that the possible
immunologic and protective interrelationships of these
new products be investigated. Studies are in progress by
the IPTi Consortium to address these issues http://
www.ipti-malaria.org [7].
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